BioCentury | Aug 21, 2020
Product Development

Basket trials carry tumor-agnostic drug development forward

Tumor-agnostic drug development has been slow to catch on, but with wider adoption of gene sequencing and a steady flow of new targeted therapy approvals, companies are starting to re-draw the lines that...
BioCentury | Apr 24, 2020
Emerging Company Profile

FoRx: A broader look at DNA damage repair has identified novel targets in the pathway using siRNA screens. Initial targets identified, including POLD3...
...cancer 1 early onset BRCA2 - Breast cancer 2 early onset PARP - Poly(ADP-ribose) polymerase POLD3...
BioCentury | Jul 23, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Polymerase (DNA directed), delta 2, regulatory subunit 50kDa (POLD2); cytochrome c, somatic (CYCS); metallothionein 1A (MT1A; MTC); aldo-keto reductase family 1, member C3...
Items per page:
1 - 3 of 3